Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06034925 · ClinicalTrials.gov registry record · Phase 4
Maribavir vs. Valganciclovir for CMV Prophylaxis in High-Risk Kidney Transplant Recipients
A Phase 4 study, sponsored by Medical University of South Carolina.
- Completed
- Registry status
- Phase 4
- Development phase
- 70
- Enrollment target
NCT06034925 is a Phase 4 study that has completed, run by Medical University of South Carolina. The registered enrollment target is 70 participants.
The verdict
NCT06034925, a Phase 4 study, has completed, sponsored by Medical University of South Carolina.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 70 participants
- Enrollment target
Study Summary
The purpose of this study is to find out if there is a difference in how well the standard MUSC cytomegalovirus (CMV) prevention medicine works, compared to a different medicine, in preventing CMV infections in kidney transplant recipients who are at risk for this type of infection, while also assessing the tolerability of these two regimens. The two medication regimens being compared are Valganciclovir (FDA approved to prevent and treat CMV infection) vs Maribavir (FDA approved to treat CMV infection) plus Acyclovir (FDA approved to prevent HSV infection).
Interventions
- DRUG Valganciclovir
- DRUG Maribavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2023-11-06 |
| Est. Completion | 2025-08-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06034925
The ClinicalTrials.gov registry entry for NCT06034925 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Valganciclovir is the first listed.
NCT06034925 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06034925 about?
NCT06034925 is a clinical study titled "Maribavir vs. Valganciclovir for CMV Prophylaxis in High-Risk Kidney Transplant Recipients". The purpose of this study is to find out if there is a difference in how well the standard MUSC cytomegalovirus (CMV) prevention medicine works, compared to a different medicine, in preventing CMV infections in kidney transplant recipients who are at risk for this type of infection, while also asses...
What is the current status of trial NCT06034925?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 70 participants. The study started on 2023-11-06. Estimated completion is 2025-08-30.
What interventions are being tested in trial NCT06034925?
The interventions under investigation include: Valganciclovir (DRUG), Maribavir (DRUG).
Who is sponsoring clinical trial NCT06034925?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.